The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer

People, 18 years old and older, who meet all the following criteria.

• Have colon cancer that is deficient in mismatch repair (dMMR) or microsatellite instability high (MSI-H)
• Have localized colon cancer (cancer that has not spread to other parts of the body)
• Have tumor that is evaluated by endoscopic test
• Are willing to undergo repeated endoscopic tests
• (Women who are potential childbearing) have negative pregnancy tests within 7 days prior to the study enrollment  
• Use contraception prior to study enrollment, duration of study and 4 months after taking the last cemiplimab
• Are willing to visit an enrolling hospital for follow-up
• Are willing to provide blood samples
• Give informed consent
• Are able to follow study instructions

People under 18 years old who:

• Do not recover from side effects of prior therapy
• Have other severe diseases including heart diseases, active infection and respiratory disease that require oxygen therapy
• Have HIV infection and currently take medication
• Are receiving other medication of clinical trial, or other therapy including chemotherapy for colon cancer
• People who are pregnant or breastfeeding
• Are willing to have children during the study or within 120 days after the last treatment
• Undergo surgery within 3 weeks prior to the study treatment
• Receive chemotherapy within 2 weeks prior to the study treatment
• Undergo radiation therapy 2 weeks prior to the study treatment
• Receive prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD L2 agent
• Have a prior or concurrent cancer that interfere with the assessment of safety and effectiveness for the study treatment
• Have metastatic cancer excluding lymph nodes metastasis
• Have active autoimmune disease that required treatment within one year
• Have a history of pneumonitis that required steroids